Also from this source

You just read:

MAP Pharmaceuticals to Present Data Showing Low Migraine Recurrence Rates With LEVADEX™ in FREEDOM-301 Trial

News provided by

MAP Pharmaceuticals, Inc.

Oct 29, 2010, 07:00 ET